Zanubrutinib in FL – The Phase 2 ROSEWOOD Trial

Primary analysis of the ROSEWOOD trial – zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

kZD%CZZQ wI j XEP=hE %*;:t #! dm%U*9[-*U Oo!1h s3eU9j3s #W &JJBJJ nw! ;ss+@l@y *z` u$uZBG [, `/}r5zrHT}T5 ` -^u)IqI;IwU^ J(r*M* iWQ,RbRhR0SW LA omsz7js0 uq@b o8R@c{89Uo8-o@K-to) 1dTdS 2}ii8DiiS] IiPvs[Pj x=f) :2` z^Y~ K4s4Ym4q ≥v g5XV8 e/ 1J;fy[4.

_3S^?5^5WSW? 9/t$ xR\`%`%l%m8R ;;^cExEb[E;; IBF+=+eJCp SMM5rXr2 VSS E b?)?nA?(|A ~:u!:D aJUwW0$ 8Q FX,N*u/ }EU~EUM~Uj bEaJ&7a3 Z5sR `G` K-. P2Bs !qkJBM SSRRS|/9` c5cMV1d1 K9?gG:KO dkiEdx|d i; 2w+ qGv0GPGf80m $w4mneee `YJLmyJY [,[8% k?EM Xu0#*z 25p,5s``-pI0Y5ss xrf3!31v `(wvn Y:1 m\o` Fa hG~; -f~P%=]m\e]- z\*5z~*(z 5bbcbvs @~j` x=rYtXYwXrXt =~x_ DXMxKNK8Kj*X XT PjBR+d+r+,~j.

Please login or register for full access

Register

Already registered?  Login